The Claim
In a 44-year-old woman with alopecia universalis and Hashimoto thyroiditis, long-term treatment with JAK inhibitors (tofacitinib, baricitinib, and ritlecitinib) was associated with normalization of thyroid peroxidase antibodies from 166 IU/mL to undetectable levels and discontinuation of levothyroxine therapy, resulting in sustained euthyroidism and absence of thyroid-related symptoms.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
A 44-year-old woman with autoimmune hair loss and thyroid inflammation experienced a reduction in thyroid antibodies and was able to stop thyroid hormone medication after taking JAK inhibitor drugs for eight years, with her thyroid function remaining normal without symptoms.
See the scientific wording
In a 44-year-old woman with alopecia universalis and Hashimoto thyroiditis, treatment with JAK inhibitors (tofacitinib, baricitinib, and ritlecitinib) over eight years was associated with normalization of thyroid peroxidase antibodies from 166 IU/mL to undetectable levels and discontinuation of levothyroxine therapy, with sustained euthyroidism and absence of thyroid-related symptoms.
What the research says
1 studyA woman with two autoimmune conditions took a special immune-suppressing drug for hair loss, and unexpectedly, her thyroid inflammation improved so much that she no longer needed thyroid medication and her blood tests returned to normal.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.